Buserelin

Buserelin Acetate

Therapeutic Indications

Buserelin is indicated for:

Advanced hormone dependent prostatic carcinoma

Men inly, only Adults (18 years old or older)

Buserelin is indicated For the treatment of advanced hormone dependent prostatic carcinoma (stage C or stage D according to the classification of Murphy et al, in Cancer 45, p1889-95, 1980) in which suppression of testosterone is indicated; however, not after bilateral orchiectomy (no further reduction of testosterone level by buserelin to be expected).

Buserelin acts by blockade and subsequent down-regulation of pituitary LHRH receptor synthesis. Gonadotropin release is consequently inhibited. As a result of this inhibition there is reduced stimulation of testosterone secretion and serum testosterone levels fall to castration range. Before inhibition occurs there is a brief stimulatory phase during which testosterone levels may rise.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Subcutaneous - 1.5 mg in 3 divided doses daily

Treatment 2: Nasal - 1.2 mg in 6 divided doses daily

Treatment 3: Subcutaneous - 9.45 mg once every 3 months

Contraindications

Active ingredient Buserelin is contraindicated in the following cases:

Lactation

No gender/age discrimination

Buserelin passed into breast milk in small amounts. Although negative effects on the infant have not been observed, it is recommended that breast-feeding be avoided during treatment with Suprefact in order to prevent the infant from ingesting small quantities of buserelin with breast milk.

Pregnancy

No gender/age discrimination

Buserelin is contraindicated in pregnancy. It is intended for the treatment of advanced prostatic carcinoma, it should not be used in pregnant or lactating women.

Radical bilateral orchiectomy

No gender/age discrimination